Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1986-01-27
1987-04-21
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Lymphokine
424 85, 530387, A61K 3942
Patent
active
046595635
ABSTRACT:
Normal plasma from donors who have not necessarily been vaccinated with a respiratory syncytial virus vaccine can be screened for higher than normal titers of naturally occurring antibody to respiratory syncytial virus (e.g. minimum ELISA titer of at least 1:110,000). Those plasmas with high titers of such antibody can be pooled and fractionated to give hyperimmune globulin. The product may be treated to render it suitable for intravenous injection. Patients with respiratory syncytial virus infection or at risk of such infection, may receive the present product to raise serum antibody titers to respiratory syncytial virus. Resultant product has an ELISA anti-RSV titer of at least about 1:250,000.
REFERENCES:
patent: 3903262 (1975-09-01), Pappenhagen et al.
patent: 4174388 (1979-11-01), McAleer et al.
patent: 4186192 (1980-01-01), Lundblad et al.
patent: 4396608 (1983-08-01), Tenold
patent: 4499073 (1985-02-01), Tenold
Richardson et al., C.A. 89 #74058j (1978) of Infect. Immun. 1978 20(3): 660-4, "Enzyme-Linked Immunosorbent Assay for Measurement of Serological Response to Respiratory Syncytial Virus Infection".
Giblin James A.
Miles Laboratories Inc.
Rose Shep K.
Simonton Pamela A.
LandOfFree
High titer anti-respiratory syncytial virus intravenous immune g does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High titer anti-respiratory syncytial virus intravenous immune g, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High titer anti-respiratory syncytial virus intravenous immune g will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-750745